Use of clinical data no longer mandatory in clinical evaluation under EU-MDR proposal?

One of the most consequential changes introduced by the EU Medical Device Regulation (EU-MDR) was the near-universal requirement to rely on clinical data as part of the clinical evaluation. The definition of clinical data was deliberately narrow and, in many cases, effectively required manufacturers to generate in-human clinical investigation data with the device itself. For many medium-risk devices, this represented a step-change in regulatory burden—particularly when compared with the US system, where similar devices often qualify for the 510(k) pathway and can reach the market without generating new clinical data.

On 16 December—quietly, and just ahead of the holiday period—the European Commission published a 170-page proposal outlining potential simplifications to the EU-MDR. Unsurprisingly, many in the industry may not yet have worked through the details. The document is dense and technical, and understanding its implications requires a careful “spot-the-difference” comparison against the existing regulation.

Buried within this proposal are several subtle but potentially far-reaching changes to the rules governing clinical evaluation. Taken together, they raise an important question for manufacturers: does the proposed text still require conformity assessment to be based on manufacturer-specific clinical data in all but exceptional cases—or is the door being reopened to alternative routes for demonstrating safety and performance, particularly for medium-risk and well-understood devices?

Rationale for the proposed changes

The proposal starts promisingly in the preamble of the draft change:

(9) “Clinical data are an important source of information for demonstrating the safety and performance of a device. However, the process of generating clinical data is often lengthy and costly. The definition of clinical data should be broadened to enable the use of data generated through studies on the device concerned that are published in scientific literature, but not necessarily peer-reviewed.”

and:

(38) “As the safety and performance of many devices other than high-risk devices can be sufficiently demonstrated using non-clinical data, including NAMs [New Approach Methodologies, replacements for animal testing], the possibility to use non-clinical data to confirm the safety and performance of a device in the conformity assessment should therefore be made more prominent in Regulation (EU) 2017/745.”

These statements clearly acknowledge the challenges manufacturers have faced under EU-MDR and express an intent to widen the available approaches for demonstrating safety and performance. However, preambles only state intent and do not carry legal force. To understand the real implications, it is therefore necessary to examine the actual proposed changes to the regulatory text.

Changes in the definition of clinical data

The proposed changes to the definition of clinical data (see figure below) are relatively small but potentially meaningful. Studies published in the scientific literature (possibly even if not peer-reviewed) that involve the manufacturer’s own device now appear to qualify as clinical data.

Artikelcontent
Proposed changes to the definition of clinical data.

The addition off “other studies … on the device concerned” could be relevant for companies that have conducted clinical investigations outside the EU. Under the current framework, only clinical investigations that were pre-announced to competent authorities (so-called “Article 62 studies”) can formally be used as part of the conformity assessment. The revised definition may therefore create additional options for manufacturers who did not fully comply with these procedural requirements at the time, but who nevertheless possess relevant published clinical data.

In addition, a separate proposed change means that, if a manufacturer of a Class IIb implantable or Class III device wishes to use clinical data from a device for which equivalence is claimed, a written contract between the manufacturers would no longer be required, provided that the original clinical evaluation was performed in compliance with the Regulation and that the manufacturer can provide clear evidence of this to the notified body.

What this could mean in practice

If adopted as proposed, this change may:

  • Reduce the regulatory “penalty” for clinical investigations conducted outside the EU that were not formally registered as “Article 62” studies. We have a number of clients where this was a potential problem.
  • Increase the formal position of investigator-initiated studies involving the manufacturer’s own device
  • Slightly ease equivalence-based strategies for Class IIb and III device by removing the contractual requirements.

Proposed changes to the clinical evaluation procedure (Article 61)

The potentially most impactful change is a very small textual modification to the first paragraph of Article 61 on clinical evaluation.

Previously, the regulation stated:

“Confirmation of conformity […] shall be based on clinical data providing sufficient clinical evidence […]”

This wording explicitly required conformity assessment to be based on clinical data. Based on the old definition of clinical data this often required formal (“article 62”) clinical investigations with the own device. The proposed text replaces this with:

“The manufacturer shall specify and justify the level of clinical evidence necessary to confirm the safety and performance of the device. That level of clinical evidence shall be appropriate in view of the characteristics of the device and its intended purpose, taking into consideration paragraph 10.”

Notably, this revised wording refers only to clinical evidence, and no longer explicitly to clinical data. When read in isolation this may appear subtle, but when combined with the proposed changes to Article 61(10), it appears to broaden the circumstances under which manufacturer-specific clinical data may not be required.

Proposed changes to Article 61(10)

Article 61(10) is currently somewhat infamous. While often perceived by manufacturers as an exemption from the requirement to collect clinical data, in practice it is applied only in a very narrow set of cases (see BSI white paper)—such as disinfectants, sterilisers, medical refrigerators, and basic tools like forceps, surgical gloves, and drapes with a long history of safe use. Invoking this provision typically triggers extensive discussions with notified bodies.

The proposed changes to Article 61(10), highlighted in the figure below, are therefore particularly noteworthy.

Artikelcontent
Proposed changes to Article 61(10)

The revised text explicitly allows information relating to a “generic device group” to be used as part of the justification for why clinical data are not appropriate. A generic device group is newly defined as:

“a set of devices having the same or similar intended purposes and a commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics.”

This raises important questions about what types of data might qualify. Could this include general literature reviews, post-market surveillance data, or vigilance data from similar products? The concept appears broader than traditional equivalence claims and may extend beyond data tied to a single reference device.

The explicitly mentioned additional sources of non-clinical data are also noteworthy, particularly in the context of the ongoing shift in biological evaluation away from animal testing toward New Approach Methodologies (NAMs).

What this could mean in practice

If interpreted broadly, the revised Article 61(10) could:

  • Enable manufacturers to rely on generic device group rather than device-specific comparators as part of rational for the lack of (own) clinical data.
  • Reduce dependence on strict equivalence arguments tied to a single reference device
  • Increase the strategic importance of post-market and vigilance data across portfolios
  • Strengthen the role of non-clinical methods (including NAMs) in overall evidence generation

At the same time, the concept of a “generic device group” is new and untested, and its practical application will depend heavily on how notified bodies interpret acceptable boundaries and data relevance.

Conclusion

It is important to emphasize that these changes are only proposals. They may still be amended, narrowed, or ultimately not adopted at all. Nevertheless, the direction of travel is noteworthy. The proposed wording suggests a deliberate shift away from an automatic assumption that manufacturer-specific clinical investigations are always required, toward a more flexible framework in which manufacturers must define, justify, and defend the level of clinical evidence appropriate for their device.

For some manufacturers, particularly those developing medium-risk devices based on established technologies, this could represent a meaningful opportunity to rethink clinical and regulatory strategies. At the same time, increased flexibility in the legislation is likely to be accompanied by greater scrutiny of the manufacturer’s justification and potentially greater variability in how notified bodies interpret and apply the rules.

If implemented, these changes are unlikely to eliminate debate with notified bodies, but they may change the nature of that debate. Success may depend less on whether clinical data exist, and more on the strength, coherence, and credibility of the overall evidence strategy.

Until any changes to Article 61 come into force, our advice to clients remains unchanged: wherever possible, include at least some clinical data (under the current, stricter definition) as part of the clinical evaluation. Doing so avoids the need to argue that clinical data are not appropriate under Article 61(10), a position that typically leads to complex and protracted discussions with notified bodies. Where no pivotal clinical data are yet available, it is often preferable to build the justification under Article 61(1) that the limited clinical data is deemed sufficient. For example by demonstrating that the first-in-human data, when considered alongside pre-clinical testing, bench data, and relevant literature, provide sufficient clinical evidence to confirm safety and performance. In practice, this approach tends to be less contentious, as it allows for a more nuanced, risk-based discussion with notified bodies rather than a binary debate about whether clinical data are required at all.

Erik 02

Erik van Dijk

Managing Partner

Don’t hesitate to ask us your questions.

Drop an e-mail or contact us via LinkedIn

This website uses cookies to ensure you get the best experience on our website. If you want to get more information about this, please view our privacy policy page.